Ran Frenkel, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 1,991 shares at $9.86 ($20K) on 2022-02-07, disclosed to the SEC on 2022-02-09.
Open-market sale of $20k KPTI by EVP, Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KPTI | SELL | 2021-02-22 | $43K | — | Filing → |
| KPTI | SELL | 2021-02-17 | $32K | — | Filing → |
| KPTI | SELL | 2020-05-11 | $39K | — | Filing → |